Does presurgical treatment destroy important prognostic information by Dixon, J Michael
Introduction
There are two common forms of presurgical treatment: a
short course of treatment up to 2 weeks before surgery, and
more prolonged periods of systemic therapy, commonly
known as neoadjuvant therapy. Short courses of treatment
have little effect on the major prognostic factors, with the
possible exception of tumour grade. In particular, tumour size
and node status do not change. In contrast, more prolonged
courses of neoadjuvant therapy are used because they have
a major influence on tumour size and, in some patients, node
status. This review investigates the commonly used prog-
nostic factors and how presurgical treatment might influence
these factors.
There are two generally used methods for estimating prog-
nosis. One is to use the Nottingham Prognostic Index (NPI)
and the other is to use Adjuvantonline [1], an online tool that
not only predicts outcome but also allows an assessment of
the effects of both endocrine therapy and chemotherapy. The
NPI relies on three factors, namely tumour size as measured
in centimetres by the pathologist at surgery, histological
tumour grade and histological node status. Adjuvantonline
uses the same three factors but adds to these the patient’s
age, the general health of the patient and the oestrogen
receptor (ER) status.
A number of these prognostic factors are affected by
presurgical treatment with hormonal therapy or chemo-
therapy. Does the use of such therapy make it more difficult
to assess prognosis, and does it destroy the ability to use
these traditional prognostic factors?
Traditional prognostic factors in patients
receiving presurgical therapy
Tumour size
Tumours do shrink following prolonged courses of pre-
surgical neoadjuvant therapy, so the size of the cancer at
subsequent surgery is likely to differ significantly from the
initial tumour size. Tumour size at diagnosis can, however, be
assessed by imaging. Studies have shown that ultrasound [2]
and magnetic resonance imaging (MRI) [3] can accurately
assess tumour size. These modalities can also be used to
assess response, and all patients receiving neoadjuvant
therapy should have preoperative ultrasound and many will
have MRI. Even in the absence of an accurate measure of
tumour size by the pathologist using imaging at diagnosis, it
should thus be possible in most patients to gain an accurate
assessment of initial tumour size. Studies have also shown
that, even after neoadjuvant endocrine therapy, baseline
tumour size correlates with breast cancer specific outcome
despite the intervening neoadjuvant therapy [4].
Node status
Node status at diagnosis can be assessed using imaging
together with fine needle aspiration (FNA), cytology, or core
biopsy of any suspicious nodes. Using this combination of
tests it is possible to identify approximately 50% of patients
with involved nodes, but importantly it does identify the
majority of patients with multiple involved nodes [5]. Some
assessment of axillary lymph node status is thus possible
even in patients receiving neoadjuvant therapy. There is
evidence in the literature that patients, particularly after neo-
adjuvant chemotherapy, change their node status and
patients who were previously node positive become node
negative [6]. Such patients have an improved prognosis,
particularly if the sterilization of the nodes is combined with a
complete response within the breast. For patients who come
to surgery after a course of neoadjuvant therapy, node status
at that time remains a highly significant indicator of prognosis,
whether this is after neoadjuvant chemotherapy or after
neoadjuvant endocrine therapy.
Tumour grade
Histological grade can be assessed on the initial diagnostic
core biopsy. Studies that have correlated grade on core
biopsy with a subsequent grade at surgery show that it is
accurate in about 60% of tumours [7]. Grade does change
with both short courses and neoadjuvant treatment, and there
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downgrade have a better response and long-term outlook [8].
Oestrogen receptor status
Both ER and progesterone receptor status are best assessed
on the initial diagnostic core biopsy at diagnosis, because of
the rapid penetration of fixative into such small specimens.
Information on hormone receptor status is thus not influenced
by presurgical therapy.
HER2 status
Although not incorporated into the currently used prognostic
indices, the HER2 status of the tumour does predict patient
outcome and can be measured accurately on the initial core
biopsy. It is thus available for all patients receiving pre-
operative therapy, and an assessment of HER2 status is
currently used to determine whether patients should be given
chemotherapy alone or preoperative chemotherapy combined
with trastuzumab.
Newer prognostic factors
Studies have shown that gene profiling of the tumour at
diagnosis correlates with long-term outcome [1]. It is possible
to carry out such studies on the initial core biopsy. Hence,
whether the patient is treated with surgery initially or receives
presurgical therapy, baseline gene profiling can be available if
fresh tissue is stored at the time of the initial diagnostic core
biopsy.
Prognostic factors in patients undergoing
neoadjuvant therapy
One potential advantage of neoadjuvant therapy is that as a
consequence of the treatment more information on the
tumour is obtained and this information itself has prognostic
value.
Response to treatment
Histological response after neoadjuvant chemotherapy has
important prognostic implications. Patients who have a com-
plete pathological response have a much better outlook than
do patients who still have residual tumour after therapy [6].
Biological measurements
The degree of proliferation as measured by Ki67 in a tumour
at diagnosis has been identified as a predictive factor on
univariate analysis, but proliferation often fails to maintain its
independent significance on multivariate analysis because
tumour grade already incorporates an assessment of the
mitotic rate. Following neoadjuvant therapy it is possible to
assess both the change and the level of residual proliferation.
Studies have shown that after neoadjuvant endocrine
therapy, there are rapid falls in proliferation shortly after
treatment has started [9,10]. After these rapid falls, the
majority of cancers maintain this fall, although in some
cancers by 3 months the proliferation rises close to baseline
levels [10]. A number of studies have shown that both the
percentage reduction in proliferation and the level of residual
proliferation after treatment are powerful prognostic factors,
both for local recurrence and subsequent breast cancer
specific survival [4,10].
Changes in gene expression during treatment
There have been no studies carried out of changes in gene
expression and correlation with outcomes after chemo-
therapy, but studies have been conducted in patients treated
with neoadjuvant letrozole [11]. One of these studies
correlated gene expression at baseline, after 2 weeks and
changes during the first 2 weeks of therapy with subsequent
response. This study has shown that although some baseline
and day 14 gene expression profiles do correlate with
response, the most accurate predictors of response are
changes in gene expression. Those tumours that did respond
had a consistent pattern of gene expression change. In
contrast, those tumours that were resistant to therapy
exhibited a variety of patterns. There thus appears to be a
consistent signature for response to endocrine therapy but a
diverse signature for resistance [12].
Discussion
From the evidence presented, many of the factors that are
currently used to estimate prognosis can be measured or
estimated even in patients undergoing neoadjuvant therapy.
Changes within the tumour that occur as a consequence of
the therapy also have prognostic significance. There is thus a
greater amount of information available to predict prognosis
in patients who undergo neoadjuvant chemotherapy than in
patients who have surgery as their initial treatment. The
National Surgical Adjuvant Breast and Bowel Project
(NSABP) study of preoperative versus postoperative chemo-
therapy showed that although it is true that different factors
predicted outcome in the neoadjuvant group, the outcomes
for each decile of patients as calculated using prognostic
factors was identical [6]. Thus, the top 10% of patients as
predicted by the prognostic factors receiving neoadjuvant
chemotherapy had an identical outcome to the top 10% in
the adjuvant group. In other words, whether the patients had
neoadjuvant therapy or not did not influence the ability to
predict survival. The conclusion must therefore be that
whatever neoadjuvant therapy does to the cancer, it does not
improve or reduce our ability to predict prognosis.
There is increasing emphasis on measuring gene expression.
It may be possible in the future to treat patients with a short
course of presurgical treatment and, by analyzing the
changes in the tumour that occur as a consequence of
treatment, to determine the effectiveness of the treatment
(and thus how an individual patient’s cancer should be
treated) but also to gain prognostic information on long-term
outcome. One problem with the current tools for prognosis is
that they provide information on the percentage chance of a
group of women with a particular type of tumour being alive
and disease free, but they are of little value in the individual
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patient. It is for this reason that further studies of the dynamic
changes in individual patients that occur as a result of therapy
continue to be investigated.
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